All posts by medical

Biochemistry

Automatic Biochemistry Analyzers Market Steady Growth to Be Witnessed by 2020-2029 – Scientect

In this report, the global Automatic Biochemistry Analyzers market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Automatic Biochemistry Analyzers market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Automatic Biochemistry Analyzers market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2637505&source=atm

The major players profiled in this Automatic Biochemistry Analyzers market report include:

Market Segment AnalysisThe research report includes specific segments by Type and by Application. Each type provides information about the production during the forecast period of 2015 to 2026. Application segment also provides consumption during the forecast period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by TypeFloor-standingBench-top

Segment by ApplicationPrimary HospitalProvincial HospitalPrefectural Hospital

Global Automatic Biochemistry Analyzers Market: Regional AnalysisThe report offers in-depth assessment of the growth and other aspects of the Automatic Biochemistry Analyzers market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

Global Automatic Biochemistry Analyzers Market: Competitive LandscapeThis section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2637505&licType=S&source=atm

The study objectives of Automatic Biochemistry Analyzers Market Report are:

To analyze and research the Automatic Biochemistry Analyzers market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Automatic Biochemistry Analyzers manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Automatic Biochemistry Analyzers market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the Automatic Biochemistry Analyzers market.

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2637505&source=atm

The rest is here:
Automatic Biochemistry Analyzers Market Steady Growth to Be Witnessed by 2020-2029 - Scientect

Biochemistry

o Aminoanisole Market 2020 Industry Growth by Jiaxing Zhonghua Chemical, WeifangUnion Biochemistry, Seya Industries Ltd, Anhui Haihua Chemical…

Courant Market Research Reports added Latest Research Report titled Global o Aminoanisole Market Status and Trend Report 2015-2025 to its research database. This report gives detailed survey of the market by examining changing aggressive elements of the o Aminoanisole Market. It helps in understanding the key product sectors and their future. It gives pin point analysis of changing rivalry flow and keeps you in front of contenders.

Request Free Sample Report of o Aminoanisole Market Report @ https://courant.biz/report/o-aminoanisole-global-market/39523/

Our Free Complimentary Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology

It offers a forward looking point of view on various elements driving or limiting business sector development. It gives a forecast based on how the market is anticipated to develop. Their key financials, general organization review, weighted SWOT examination, key advancements, developments, land spread, and procedures are contemplated and have been skillfully made in this far reaching o Aminoanisole Market report.

The o Aminoanisole Market report covers a top to bottom focused scene in which key players are profiled. Different producers engaged with the o Aminoanisole Market are surveyed. Research report for o Aminoanisole Market incorporates a worldwide viewpoint. This report investigates o Aminoanisole Market based on its market fragments, chief geologies, and current market patterns. This can bolster the user in settling on educated choices and major key systems.

Download Free PDF Report Brochure @ https://courant.biz/report/o-aminoanisole-global-market/39523/

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

This can bolster the user in settling on educated choices and major key systems. The beat of the market is unveiled in this sector which can enable the user in applying key strategies to attain competitive benefit. Such a top to bottom, far reaching research survey conveys the genuinely necessary esteem expansion, with unbiased measurable analysis and key suggestions, which can be utilized to design future extensions and enhance current position in the o Aminoanisole Market in a specific area.

Imperative areas all over the globe are secured and the patterns, advancements, drivers, restrictions, and difficulties affecting the development of the o Aminoanisole Market over these vital regions are considered. An evaluation of the effect of government strategies and holistic on the market processes is likewise included to give an all encompassing outline of the o Aminoanisole Market future viewpoint.

Inquire more about this report @ https://courant.biz/report/o-aminoanisole-global-market/39523/

Browse Full Report @ https://courant.biz/report/o-aminoanisole-global-market/39523/

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

Originally posted here:
o Aminoanisole Market 2020 Industry Growth by Jiaxing Zhonghua Chemical, WeifangUnion Biochemistry, Seya Industries Ltd, Anhui Haihua Chemical...

Biochemistry

Chitin and Chitin Derivatives Market Size, Key Trends, Challenges and Standardization, Research, Key Players, Economic Impact and Forecast to 2026 |…

LOS ANGELES, United States:The report titled Global Chitin and Chitin Derivatives Market is one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Chitin and Chitin Derivatives market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Chitin and Chitin Derivatives market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Chitin and Chitin Derivatives market is carefully analyzed and researched about by the market analysts.The market analysts and researchers have done extensive analysis of the global Chitin and Chitin Derivatives market with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided accurate and reliable market data and useful recommendations with an aim to help the players gain an insight into the overall present and future market scenario. The Chitin and Chitin Derivatives report comprises in-depth study of the potential segments including product type, application, and end user and their contribution to the overall market size.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/sample-form/form/2106508/global-and-united-states-chitin-and-chitin-derivatives-market

In addition, market revenues based on region and country are provided in the Chitin and Chitin Derivatives report. The authors of the report have also shed light on the common business tactics adopted by players. The leading players of the global Chitin and Chitin Derivatives market and their complete profiles are included in the report. Besides that, investment opportunities, recommendations, and trends that are trending at present in the global Chitin and Chitin Derivatives market are mapped by the report. With the help of this report, the key players of the global Chitin and Chitin Derivatives market will be able to make sound decisions and plan their strategies accordingly to stay ahead of the curve.

Competitive landscape is a critical aspect every key player needs to be familiar with. The report throws light on the competitive scenario of the global Chitin and Chitin Derivatives market to know the competition at both the domestic and global levels. Market experts have also offered the outline of every leading player of the global Chitin and Chitin Derivatives market, considering the key aspects such as areas of operation, production, and product portfolio. Additionally, companies in the report are studied based on the key factors such as company size, market share, market growth, revenue, production volume, and profits.

Key Players Mentioned in the Global Chitin and Chitin Derivatives Market Research Report: Agratech, ADVANCED BIOPOLYMERS, Novamatrix, Bioline, Golden Shell, Primex, Haixin, Haizhiyuan, Yunzhou, Hecreat, Bannawach Bio-Line, Hubei Huashan, Jiangsu Shuanglin Marine Biological, Golden-Shell Pharmaceutical, Zhejiang New Fuda Ocean Biotech, Weifang Haizhiyuan Biological, Ningbo Zhenhai Haixin Biological, Jinlong, Fengrun Biochemical, Qingdao Yunzhou Biochemistry

Chitin and Chitin Derivatives Market Types: Food GradeIndustrial Grade

Chitin and Chitin Derivatives Market Applications: AgricultureIndustrialMedicineOthers

The Chitin and Chitin Derivatives Market report has been segregated based on distinct categories, such as product type, application, end user, and region. Each and every segment is evaluated on the basis of CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is estimated to generate opportunities in the global Chitin and Chitin Derivatives market in the forthcoming years. This segmental analysis will surely turn out to be a useful tool for the readers, stakeholders, and market participants to get a complete picture of the global Chitin and Chitin Derivatives market and its potential to grow in the years to come.

Key questions answered in the report:

Request for customization in Report: https://www.qyresearch.com/customize-request/form/2106508/global-and-united-states-chitin-and-chitin-derivatives-market

Table of Contents:

1 Study Coverage1.1 Chitin and Chitin Derivatives Product Introduction1.2 Market Segments1.3 Key Chitin and Chitin Derivatives Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Chitin and Chitin Derivatives Market Size Growth Rate by Type1.4.2 Food Grade1.4.3 Industrial Grade1.5 Market by Application1.5.1 Global Chitin and Chitin Derivatives Market Size Growth Rate by Application1.5.2 Agriculture1.5.3 Industrial1.5.4 Medicine1.5.5 Others1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Chitin and Chitin Derivatives Market Size, Estimates and Forecasts2.1.1 Global Chitin and Chitin Derivatives Revenue 2015-20262.1.2 Global Chitin and Chitin Derivatives Sales 2015-20262.2 Global Chitin and Chitin Derivatives, Market Size by Producing Regions: 2015 VS 2020 VS 20262.3 Chitin and Chitin Derivatives Historical Market Size by Region (2015-2020)2.3.1 Global Chitin and Chitin Derivatives Retrospective Market Scenario in Sales by Region: 2015-20202.3.2 Global Chitin and Chitin Derivatives Retrospective Market Scenario in Revenue by Region: 2015-20202.4 Chitin and Chitin Derivatives Market Estimates and Projections by Region (2021-2026)2.4.1 Global Chitin and Chitin Derivatives Sales Forecast by Region (2021-2026)2.4.2 Global Chitin and Chitin Derivatives Revenue Forecast by Region (2021-2026)

3 Global Chitin and Chitin Derivatives Competitor Landscape by Players3.1 Global Top Chitin and Chitin Derivatives Sales by Manufacturers3.1.1 Global Chitin and Chitin Derivatives Sales by Manufacturers (2015-2020)3.1.2 Global Chitin and Chitin Derivatives Sales Market Share by Manufacturers (2015-2020)3.2 Global Chitin and Chitin Derivatives Manufacturers by Revenue3.2.1 Global Chitin and Chitin Derivatives Revenue by Manufacturers (2015-2020)3.2.2 Global Chitin and Chitin Derivatives Revenue Share by Manufacturers (2015-2020)3.2.3 Global Chitin and Chitin Derivatives Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Chitin and Chitin Derivatives Revenue in 20193.2.5 Global Chitin and Chitin Derivatives Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Global Chitin and Chitin Derivatives Price by Manufacturers3.4 Global Chitin and Chitin Derivatives Manufacturing Base Distribution, Product Types3.4.1 Chitin and Chitin Derivatives Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Chitin and Chitin Derivatives Product Type3.4.3 Date of International Manufacturers Enter into Chitin and Chitin Derivatives Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)4.1 Global Chitin and Chitin Derivatives Market Size by Type (2015-2020)4.1.1 Global Chitin and Chitin Derivatives Sales by Type (2015-2020)4.1.2 Global Chitin and Chitin Derivatives Revenue by Type (2015-2020)4.1.3 Chitin and Chitin Derivatives Average Selling Price (ASP) by Type (2015-2026)4.2 Global Chitin and Chitin Derivatives Market Size Forecast by Type (2021-2026)4.2.1 Global Chitin and Chitin Derivatives Sales Forecast by Type (2021-2026)4.2.2 Global Chitin and Chitin Derivatives Revenue Forecast by Type (2021-2026)4.2.3 Chitin and Chitin Derivatives Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Chitin and Chitin Derivatives Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)5.1 Global Chitin and Chitin Derivatives Market Size by Application (2015-2020)5.1.1 Global Chitin and Chitin Derivatives Sales by Application (2015-2020)5.1.2 Global Chitin and Chitin Derivatives Revenue by Application (2015-2020)5.1.3 Chitin and Chitin Derivatives Price by Application (2015-2020)5.2 Chitin and Chitin Derivatives Market Size Forecast by Application (2021-2026)5.2.1 Global Chitin and Chitin Derivatives Sales Forecast by Application (2021-2026)5.2.2 Global Chitin and Chitin Derivatives Revenue Forecast by Application (2021-2026)5.2.3 Global Chitin and Chitin Derivatives Price Forecast by Application (2021-2026)

6 United States by Players, Type and Application6.1 United States Chitin and Chitin Derivatives Market Size YoY Growth 2015-20266.1.1 United States Chitin and Chitin Derivatives Sales YoY Growth 2015-20266.1.2 United States Chitin and Chitin Derivatives Revenue YoY Growth 2015-20266.1.3 United States Chitin and Chitin Derivatives Market Share in Global Market 2015-20266.2 United States Chitin and Chitin Derivatives Market Size by Players (International and Local Players)6.2.1 United States Top Chitin and Chitin Derivatives Players by Sales (2015-2020)6.2.2 United States Top Chitin and Chitin Derivatives Players by Revenue (2015-2020)6.3 United States Chitin and Chitin Derivatives Historic Market Review by Type (2015-2020)6.3.1 United States Chitin and Chitin Derivatives Sales Market Share by Type (2015-2020)6.3.2 United States Chitin and Chitin Derivatives Revenue Market Share by Type (2015-2020)6.3.3 United States Chitin and Chitin Derivatives Price by Type (2015-2020)6.4 United States Chitin and Chitin Derivatives Market Estimates and Forecasts by Type (2021-2026)6.4.1 United States Chitin and Chitin Derivatives Sales Forecast by Type (2021-2026)6.4.2 United States Chitin and Chitin Derivatives Revenue Forecast by Type (2021-2026)6.4.3 United States Chitin and Chitin Derivatives Price Forecast by Type (2021-2026)6.5 United States Chitin and Chitin Derivatives Historic Market Review by Application (2015-2020)6.5.1 United States Chitin and Chitin Derivatives Sales Market Share by Application (2015-2020)6.5.2 United States Chitin and Chitin Derivatives Revenue Market Share by Application (2015-2020)6.5.3 United States Chitin and Chitin Derivatives Price by Application (2015-2020)6.6 United States Chitin and Chitin Derivatives Market Estimates and Forecasts by Application (2021-2026)6.6.1 United States Chitin and Chitin Derivatives Sales Forecast by Application (2021-2026)6.6.2 United States Chitin and Chitin Derivatives Revenue Forecast by Application (2021-2026)6.6.3 United States Chitin and Chitin Derivatives Price Forecast by Application (2021-2026)

7 North America7.1 North America Chitin and Chitin Derivatives Market Size YoY Growth 2015-20267.2 North America Chitin and Chitin Derivatives Market Facts & Figures by Country7.2.1 North America Chitin and Chitin Derivatives Sales by Country (2015-2020)7.2.2 North America Chitin and Chitin Derivatives Revenue by Country (2015-2020)7.2.3 U.S.7.2.4 Canada

8 Europe8.1 Europe Chitin and Chitin Derivatives Market Size YoY Growth 2015-20268.2 Europe Chitin and Chitin Derivatives Market Facts & Figures by Country8.2.1 Europe Chitin and Chitin Derivatives Sales by Country8.2.2 Europe Chitin and Chitin Derivatives Revenue by Country8.2.3 Germany8.2.4 France8.2.5 U.K.8.2.6 Italy8.2.7 Russia

9 Asia Pacific9.1 Asia Pacific Chitin and Chitin Derivatives Market Size YoY Growth 2015-20269.2 Asia Pacific Chitin and Chitin Derivatives Market Facts & Figures by Country9.2.1 Asia Pacific Chitin and Chitin Derivatives Sales by Region (2015-2020)9.2.2 Asia Pacific Chitin and Chitin Derivatives Revenue by Region9.2.3 China9.2.4 Japan9.2.5 South Korea9.2.6 India9.2.7 Australia9.2.8 Taiwan9.2.9 Indonesia9.2.10 Thailand9.2.11 Malaysia9.2.12 Philippines9.2.13 Vietnam

10 Latin America10.1 Latin America Chitin and Chitin Derivatives Market Size YoY Growth 2015-202610.2 Latin America Chitin and Chitin Derivatives Market Facts & Figures by Country10.2.1 Latin America Chitin and Chitin Derivatives Sales by Country10.2.2 Latin America Chitin and Chitin Derivatives Revenue by Country10.2.3 Mexico10.2.4 Brazil10.2.5 Argentina

11 Middle East and Africa11.1 Middle East and Africa Chitin and Chitin Derivatives Market Size YoY Growth 2015-202611.2 Middle East and Africa Chitin and Chitin Derivatives Market Facts & Figures by Country11.2.1 Middle East and Africa Chitin and Chitin Derivatives Sales by Country11.2.2 Middle East and Africa Chitin and Chitin Derivatives Revenue by Country11.2.3 Turkey11.2.4 Saudi Arabia11.2.5 U.A.E

12 Company Profiles12.1 Agratech12.1.1 Agratech Corporation Information12.1.2 Agratech Description and Business Overview12.1.3 Agratech Sales, Revenue and Gross Margin (2015-2020)12.1.4 Agratech Chitin and Chitin Derivatives Products Offered12.1.5 Agratech Recent Development12.2 ADVANCED BIOPOLYMERS12.2.1 ADVANCED BIOPOLYMERS Corporation Information12.2.2 ADVANCED BIOPOLYMERS Description and Business Overview12.2.3 ADVANCED BIOPOLYMERS Sales, Revenue and Gross Margin (2015-2020)12.2.4 ADVANCED BIOPOLYMERS Chitin and Chitin Derivatives Products Offered12.2.5 ADVANCED BIOPOLYMERS Recent Development12.3 Novamatrix12.3.1 Novamatrix Corporation Information12.3.2 Novamatrix Description and Business Overview12.3.3 Novamatrix Sales, Revenue and Gross Margin (2015-2020)12.3.4 Novamatrix Chitin and Chitin Derivatives Products Offered12.3.5 Novamatrix Recent Development12.4 Bioline12.4.1 Bioline Corporation Information12.4.2 Bioline Description and Business Overview12.4.3 Bioline Sales, Revenue and Gross Margin (2015-2020)12.4.4 Bioline Chitin and Chitin Derivatives Products Offered12.4.5 Bioline Recent Development12.5 Golden Shell12.5.1 Golden Shell Corporation Information12.5.2 Golden Shell Description and Business Overview12.5.3 Golden Shell Sales, Revenue and Gross Margin (2015-2020)12.5.4 Golden Shell Chitin and Chitin Derivatives Products Offered12.5.5 Golden Shell Recent Development12.6 Primex12.6.1 Primex Corporation Information12.6.2 Primex Description and Business Overview12.6.3 Primex Sales, Revenue and Gross Margin (2015-2020)12.6.4 Primex Chitin and Chitin Derivatives Products Offered12.6.5 Primex Recent Development12.7 Haixin12.7.1 Haixin Corporation Information12.7.2 Haixin Description and Business Overview12.7.3 Haixin Sales, Revenue and Gross Margin (2015-2020)12.7.4 Haixin Chitin and Chitin Derivatives Products Offered12.7.5 Haixin Recent Development12.8 Haizhiyuan12.8.1 Haizhiyuan Corporation Information12.8.2 Haizhiyuan Description and Business Overview12.8.3 Haizhiyuan Sales, Revenue and Gross Margin (2015-2020)12.8.4 Haizhiyuan Chitin and Chitin Derivatives Products Offered12.8.5 Haizhiyuan Recent Development12.9 Yunzhou12.9.1 Yunzhou Corporation Information12.9.2 Yunzhou Description and Business Overview12.9.3 Yunzhou Sales, Revenue and Gross Margin (2015-2020)12.9.4 Yunzhou Chitin and Chitin Derivatives Products Offered12.9.5 Yunzhou Recent Development12.10 Hecreat12.10.1 Hecreat Corporation Information12.10.2 Hecreat Description and Business Overview12.10.3 Hecreat Sales, Revenue and Gross Margin (2015-2020)12.10.4 Hecreat Chitin and Chitin Derivatives Products Offered12.10.5 Hecreat Recent Development12.11 Agratech12.11.1 Agratech Corporation Information12.11.2 Agratech Description and Business Overview12.11.3 Agratech Sales, Revenue and Gross Margin (2015-2020)12.11.4 Agratech Chitin and Chitin Derivatives Products Offered12.11.5 Agratech Recent Development12.12 Hubei Huashan12.12.1 Hubei Huashan Corporation Information12.12.2 Hubei Huashan Description and Business Overview12.12.3 Hubei Huashan Sales, Revenue and Gross Margin (2015-2020)12.12.4 Hubei Huashan Products Offered12.12.5 Hubei Huashan Recent Development12.13 Jiangsu Shuanglin Marine Biological12.13.1 Jiangsu Shuanglin Marine Biological Corporation Information12.13.2 Jiangsu Shuanglin Marine Biological Description and Business Overview12.13.3 Jiangsu Shuanglin Marine Biological Sales, Revenue and Gross Margin (2015-2020)12.13.4 Jiangsu Shuanglin Marine Biological Products Offered12.13.5 Jiangsu Shuanglin Marine Biological Recent Development12.14 Golden-Shell Pharmaceutical12.14.1 Golden-Shell Pharmaceutical Corporation Information12.14.2 Golden-Shell Pharmaceutical Description and Business Overview12.14.3 Golden-Shell Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)12.14.4 Golden-Shell Pharmaceutical Products Offered12.14.5 Golden-Shell Pharmaceutical Recent Development12.15 Zhejiang New Fuda Ocean Biotech12.15.1 Zhejiang New Fuda Ocean Biotech Corporation Information12.15.2 Zhejiang New Fuda Ocean Biotech Description and Business Overview12.15.3 Zhejiang New Fuda Ocean Biotech Sales, Revenue and Gross Margin (2015-2020)12.15.4 Zhejiang New Fuda Ocean Biotech Products Offered12.15.5 Zhejiang New Fuda Ocean Biotech Recent Development12.16 Weifang Haizhiyuan Biological12.16.1 Weifang Haizhiyuan Biological Corporation Information12.16.2 Weifang Haizhiyuan Biological Description and Business Overview12.16.3 Weifang Haizhiyuan Biological Sales, Revenue and Gross Margin (2015-2020)12.16.4 Weifang Haizhiyuan Biological Products Offered12.16.5 Weifang Haizhiyuan Biological Recent Development12.17 Ningbo Zhenhai Haixin Biological12.17.1 Ningbo Zhenhai Haixin Biological Corporation Information12.17.2 Ningbo Zhenhai Haixin Biological Description and Business Overview12.17.3 Ningbo Zhenhai Haixin Biological Sales, Revenue and Gross Margin (2015-2020)12.17.4 Ningbo Zhenhai Haixin Biological Products Offered12.17.5 Ningbo Zhenhai Haixin Biological Recent Development12.18 Jinlong12.18.1 Jinlong Corporation Information12.18.2 Jinlong Description and Business Overview12.18.3 Jinlong Sales, Revenue and Gross Margin (2015-2020)12.18.4 Jinlong Products Offered12.18.5 Jinlong Recent Development12.19 Fengrun Biochemical12.19.1 Fengrun Biochemical Corporation Information12.19.2 Fengrun Biochemical Description and Business Overview12.19.3 Fengrun Biochemical Sales, Revenue and Gross Margin (2015-2020)12.19.4 Fengrun Biochemical Products Offered12.19.5 Fengrun Biochemical Recent Development12.20 Qingdao Yunzhou Biochemistry12.20.1 Qingdao Yunzhou Biochemistry Corporation Information12.20.2 Qingdao Yunzhou Biochemistry Description and Business Overview12.20.3 Qingdao Yunzhou Biochemistry Sales, Revenue and Gross Margin (2015-2020)12.20.4 Qingdao Yunzhou Biochemistry Products Offered12.20.5 Qingdao Yunzhou Biochemistry Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Chitin and Chitin Derivatives Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Chitin and Chitin Derivatives Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details16.3 Disclaimer

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Read the original:
Chitin and Chitin Derivatives Market Size, Key Trends, Challenges and Standardization, Research, Key Players, Economic Impact and Forecast to 2026 |...

Biochemistry

IGNOU invites applications for BSc In Biochemistry, apply till August 31 @ Ignouadmission.samarth.edu.in – India Today

The Indira Gandhi National Open University (IGNOU) has started a new BSc (hons) programme in Biochemistry in online and distance learning (ODL) mode from July 2020. Students who have passed Class 12 exams with subjects like biology, chemistry and physics can apply for the programme at ignouadmission.samarth.edu.in.

The last date to apply for the programme is August 31, 2020. The course will be taught in English language and Hindi. The minimum duration of the programme is three years and the maximum duartion is six years. The course is available in both January and July session.

With a substantial number of courses from the discipline of Biochemistry and a few interdisciplinary and skill-enhancing courses, this Bachelor of Science Honours programme is designed to give a piece of in-depth knowledge in Biochemistry while giving the learner an opportunity to explore subjects beyond the discipline, IGNOU said.

The registration fee for the programme is Rs 200. The total fee of the programme is Rs 43,500, to be paid as annual fee of Rs 14,500 per year.

Read the original here:
IGNOU invites applications for BSc In Biochemistry, apply till August 31 @ Ignouadmission.samarth.edu.in - India Today

Embryology

The Department of Embryology Tackles Volume and Variety with Qumulo – AiThority

Qumulo, the leader in data-aware scale-out NAS, announced that the Department ofEmbryology at the Carnegie Institution for Sciencehas chosenQumulo Core to deliver the performance, scalability, and simplicity needed to keep pace with evolving research data requirements.

The Carnegie Institution for Science conducts an extensive range of pure scientific research, from earth science and biology to magnetism and astronomy. The Institutions Department of Embryology, established in 1913, is globally recognized for its innovative experimental studies, using molecular biology, genetic techniques, and animal models to investigate developmental processes from single-cell embryos to whole organisms research that has led to numerous scientific insights and three Nobel Prizes.

Recommended AI News:Coalfire Appoints Tech Power Players Akbari And Rueda To Board Of Directors

Embryologys research data can be roughly divided into three categories: images collected from microscopes and other imaging systems, nucleotide sequencing data from next-generation sequencers, and the usual variety of common document files used to collect, report and present results. While document storage is relatively straightforward, the imaging and sequencing data present substantial challenges; data sets can consist of millions of kilobyte-sized files or dozens of hundred-gigabyte files. These files are accessed for processing and analysis from client computers running all of the major operating systems (Windows, Mac OSX, Linux).

Embryology had relied on an EMC/Isilon system as its primary storage. However, that system was approaching end-of-life, and a replacement became necessary to deal with the departments increasing demands for storage, performance, and capacity.

One of our major replacement criteria was finding a storage system that could bridge that file volume and variety, says Bill Kupiec, IT Manager for Carnegies Department of Embryology. It had to handle both the streaming needed for very large data sets and the fast processing required for millions of small files. That made locating a workable solution extremely challenging.

Recommended AI News:Job.com Completes First Acquisition with Tampa IT Firm HireVergence

Qumulo is the leader in data-aware scale-out NAS, delivering flexible, fast, and highly scalable storage together with the real-time analytics necessary for visibility into data usage. The combination provides the storage performance and scale the departments team wanted, packaged in a simple and affordable appliance architecture that leverages commodity hardware.

After an exhaustive search looking at more than a dozen vendors, that ability to combine performance, scalability, and simplicity won the day. The department selected Qumulos QC208 hybrid storage appliances, deploying a four-node, NFS, and SMB-based cluster with almost a petabyte of raw capacity.

With the Qumulo cluster in place, the departments challenge of maintaining system performance across file types and sizes has rapidly become a thing of the past.

Most storage vendors tout aggregate bandwidth, which isnt relevant to us, explained Mahmud Siddiqi, Microscopy Facility Manager for the Department of Embryology. We care about how quickly each client can get files back and forth from the storage system, or how it handles high volume from a metadata or directory standpoint. Virtually every storage system we looked at addressed our aggregate load, but all stumbled when pushed by a single client. Except for Qumulo.

The team found that the new Qumulo cluster was able to quickly traverse large directories, feed high file volumes, and easily deliver or ingest large streaming files.

When the team has needed help in configuring the system, theQumulo Care support has been a quick call or an easy Slack channel away. Our interaction with the Qumulo support team has been great, noted Kupiec. Its so refreshing to have multiple people quickly, knowledgeably, and pleasantly come together to help us sort issues.

The Qumulo team is helping to keep pace with this evolution through agile two-week software sprints that continually enhance the system and help ensure its always meeting the departments needs.

Our research organization falls between the cracks for most storage vendors, with giant imaging sets and millions of tiny genetic sequencing scraps. Finding a system that reasonably handled all our complex workflows was difficult, and in the end, only Qumulo was the right fit, concluded Kupiec.

Recommended AI News:Spyse Launches a New External Threat Intelligence Solution to Prevent Cybersecurity Risks

Read more:
The Department of Embryology Tackles Volume and Variety with Qumulo - AiThority

Embryology

How having a ‘dad bod’ could affect your chances of becoming a father – Essential Baby

Getty Images/iStockphoto

Male belly fat reduces a man's chance of becoming a father by almost half, according to a new study.

The research, which was presented at the The European Society of Human Reproduction and Embryology (ESHRE) conference last month, found that every 5cm increase in a man's middle section, reduced his partner's chances of having a baby by 9 per cent at each IVF attempt.

As part of the study, researchers tracked179 couples undergoing IVFduringJanuary 2019 atMassachusetts General Hospital Fertility Center. Men's and women's height, weight and waist circumference were all measured.

"These results suggest that central obesity may be an independent risk factor for male factor infertility," the researchers, led by Harvard Public Health concluded.

According to the team, belly fat produces a chemical that turns testosterone into the female sex hormone oestrogen.

Having a 'pot belly' was especially problematic, with researchers claiming it can reducea man's chances of producing offspring by 46 per cent.

Dr Fleur Cattrall, fertility specialist at Melbourne IVF, tells Essential Baby that while we already knewa man's weight could negatively affect sperm quality, "This study is important as it shows that the higher the man's waist circumference, the lower the chance of their partner becoming pregnant with IVF."

According to Dr Cattrall, often thefocus is on the femalepartner's pre-pregnancy health. In reality, however, "conception is a team effort".

"This study shows the importance of men optimising their health, particularly their weight prior to commencing IVF treatment to increase the chances of success," Dr Cattrall says.

"Sperm production actuallytakes about three months, so I like to remind men that the sperm they are producing today was actually made six weeks ago."

Dr Cattrall notes that this encourages men to plan ahead, "to limit their alcohol intake, boost their diet with fresh fruit and vegetables and to aim for optimalweightrange as this can help develophealthysperm."

And she says the findings are particularly topical amid the COVID-19 pandemic.

"Many couples are working from home, spending more time indoors so the potential to overeat is high," Dr Cattrall says.

Read this article:
How having a 'dad bod' could affect your chances of becoming a father - Essential Baby

Genetics

NIH scientists credited with breakthrough in treating a genetic disorder – Federal News Network

Best listening experience is on Chrome, Firefox or Safari. Subscribe to Federal Drives daily audio interviews onApple PodcastsorPodcastOne.

A major breakthrough in treating a genetic disorder can be credited to our next guest. Sickle cell disease is a blood disorder that affects more than 20 million people worldwide. Theyve recently had a breakthrough. Federal News Networks Eric White spoke to one of the scientists at the National Institutes of Health conducting research on sickle cell on Federal Drive with Tom Temin. Dr. John Tisdale is a finalist in this years Service to America Medals program.

Dr. John Tisdale: I trained in internal medicine, and that was in the early 90s. I encountered patients with sickle cell disease who were experiencing extraordinary pain. And at that time, all we had was pain medication. So we would give pain medication and IV fluids because very often dehydration was what provoked the pain episode in these patients. But we had no specific treatments, nothing that were directed at the disease itself, only management of the pain. It was strange to me because I had learned about sickle cell disease in genetics classes and had known that we knew the basis for this disease longer than any other disease, yet we had no treatment, nothing. So it motivated me to think about ways that could treat the disease. The obvious thing that came to mind was a bone marrow transplant because we had a very active bone marrow transplant service at Vanderbilt. And I found that a very exciting way to approach disease and it just made sense that if you have a blood disease that causes all this difficulty in blood comes from the bone marrow well one obvious way to fix it is just to replace the bone marrow with one that doesnt have the genetics that causes the disease, like a brother or sister that we were doing for other kinds of diseases, and that could potentially cure the disease. And in fact, I learned that it had been done before in a patient who had leukemia. And that was a reason for her getting a bone marrow transplant. But she also had sickle cell disease and she was cured of both. There were some efforts during that time to bring that to the clinic, in the pediatric setting, and everything is always easier with kids because theyre tougher when it comes to medications and transplants and all the things that you can think of doing, chemotherapy. That got me motivated into studying hematology and bone marrow transplant, and trying to figure out ways to bring bone marrow transplant to patients with sickle cell disease.

Eric White: This sickle cell disease, obviously weve all heard of it. Even if you know what it is, its still a complicated disease. Can you explain what is the latest research says that sickle cell disease actually does over? As I said its a very strange disease that affects the body in many different ways. Are there any new findings as to how it does actually affect it?

Dr. John Tisdale: Well, I think weve known for a very long time exactly what happens in this disease. It arose as a way to protect from death from malaria. So just one little letter off for the gene that makes our hemoglobin, and hemoglobin is the molecule in red blood cells that carries oxygen around the blood. So one letter off in part of that molecule, and you have protection from malaria, you dont get the very severe form of malaria because the red cell is not as hospitable to the parasite. So that gets selected for in areas where theres malaria, like in Sub Saharan Africa. But if you get two copies of the gene, one from mom and one from dad, you get this disease, sickle cell disease because the hemoglobin now is different than the normal hemoglobin. Instead of carrying oxygen around and staying in solution like it does normally, you have a hemoglobin that once it does its job by dropping off oxygen out in the body, it can come out of solution and become like rock hard, distort the shape of the red cell thats normally squeezing through blood vessels to find its way back to the lungs to get more oxygen. When that happens, block the circulation. So it kind of causes a log jam and all the blood behind it gets stuck. And so wherever that happens, gets starved of its oxygen. So I mean, if it happens in the brain, for example, it causes a stroke. And so kids, eight years old can have a stroke that looks exactly like the sort that we see in the elderly who have vascular disease. If it happens in the muscle, its extremely painful or in the bone. And it happens in every organ in the body. And as a result can damage those organs over time and significantly shorten the lifespan of patients with sickle cell disease. So the lifespan currently is in the 40s. And thats much improved over the last several decades, but its still much lower than then people without the disease.

Eric White: So with your research, what has given you the most promise? What results have you all hung on to whether its bone marrow transplant or gene therapy? Is there one that you say hey, we might be on to something here?

Dr. John Tisdale: Well, I think the biggest breakthrough that weve made is figuring out just how much of the bone marrow we have to fix. So it turns out, we dont have to completely replace the bone marrow with somebody elses bone marrow to make the blood normal. So normally in a bone marrow transplant you you have to give chemotherapy to take away all of the cells that are making blood. Thats kind of like tilling the garden, right? You cant go out in the middle of a cornfield and spread a bunch of tomato seeds and expect to have tomatoes there, theyre not going to grow because the corns already growing. So the thinking is to do a bone marrow transplant, you have to harvest the corn, till the soil, plant the sees. And the same is true for bone marrow transplants. But it turns out for sickle cell disease, we dont have to do that. Weve had patients who even though we try to get rid of all their bone marrow, we failed and they had up to 80% of their own bone marrow still making blood, and presumably sickle blood. But if we had only 20% from the donor that was making normal blood, that would result in all of the blood being normal. And thats just because sickle cells live 10 or 12 days in the circulation, normal cells live 120 days in the circulation. And since the normal cells have such an advantage, you dont really have to completely eradicate the patients own bone marrow or you dont have to fix every cell. So thats important. That told us two things. One, we dont have to use toxic chemotherapy that we normally have to use to do a bone marrow transplant. And furthermore, we can start to think about gene therapy as an approach because we know we can never fix every cell. But if we could fix 20% of cells, we would predict from what weve observed in patients getting transplants from their brother or sister, that wed be able to fix the disease. And were well above the 20% mark when we transfer genes into cells. We can also correct the mutation at higher than 20%. So knowing that we only have to get to 20% has allowed us to start clinical trials, using the patients own bone marrow where we take those seeds out and try to fix them and give them back. If we can make 20%, we think we can fix the disease.

Eric White: Is there anything else that youd like to get the word out on? Is there any way people might be able to help or if if they have any family members who are suffering from this, if theres anything you would like to tell them?

Dr. John Tisdale: Well, I mean, I think the thing thats very important to understand for anyone with a genetic disease or otherwise is that clinical trials are the way that we make progress. And so participating in clinical trials is important for moving the field forward, and we partner with our patients and their family and their support structure to do these clinical trials and to make progress in the disease. So its extraordinarily important for people to understand that. Thats the way we make progress.

Continued here:
NIH scientists credited with breakthrough in treating a genetic disorder - Federal News Network

Genetics

Increased Access to Germline Testing Needed in Prostate Cancer – OncLive

Germline genetic testing is a key component of prostate cancer treatment, and broader testing criteria combined with reduced barriers to these tests could result in better informed care, including preventive surveillance, according to data from a recent study.1

Results from the retrospective study done in a total of 986 patients with prostate cancer who participated in a sponsored testing program showed that 16% (n = 153) of patients who underwent genetic testing had positive germline result; of these patients, 14% (n = 138) had pathogenic (P)/likely pathogenic (LP) variants and 1.5% (n = 15) had increased risk alleles (IRAs). Moreover, these patients were found to have 167 P/LP variants in 31 genes, as well as 19 IRAs in APC and HOXB13.

A total of 129 patients with P/LP variants had staging data available. This information indicated that 70 patients had very high-risk disease (stage III/IV), 23 had high-risk disease (stage III), and 36 had intermediate- to low-risk disease (stage IIa, IIb, and IIc). Among patients who had P/LP variants or risk alleles, only 36% reported having a family history of prostate, breast, ovarian, or pancreatic cancer.

Our initial findings from this study of [patients with] prostate cancer found an overall positive rate of 16% with 75% of positive patients being eligible for implementation of gene-specific management guidelines, precision therapies and/or clinical treatment trials, the study authors wrote. Of patients with P/LP variants, 64% did not have a close family history of prostate, breast, ovarian, or pancreatic cancer, and therefore would not have been eligible for testing based on National Comprehensive Cancer Network (NCCN) criteria.

Current criteria for germline testing in patients who have been diagnosed with prostate cancer may present a barrier to some individuals, especially those who dont have specific features regarding personal or family history, according to the investigators. Previous data have suggested that these testing criteria can exclude patients who actually harbor germline variants, which could potentially lead to suboptimal care.2

To address this, investigators launched a sponsored testing program aimed at increasing access to germline genetic testing for patients with prostate cancer through the utilization of broader criteria and eliminating cost barriers.

The program launched in July 2019 and continued throughout October 2019. Each patient enrolled on the program underwent testing that included an 84-gene, multicancer germline panel. Positive results included P and LP variants as well as IRAs. Of the 986 patients enrolled, the majority, or 70% (n = 692), were Caucasian, 13% were African American (n = 127), 3% were Hispanic (n = 33), 1.7% were Ashkenazi Jewish (n = 17), 1.0% were Asian (n = 10), and the remaining 11% (n = 107) were of unreported, mixed, or other ethnicity.

Additional results showed that when investigators evaluated diagnostic yield by disease stage, the very high-risk subgroup had a positive rate of 16%, the high-risk subgroup had a positive rate of 17%, and the intermediate- to low-risk subgroup had a positive rate of 14%.

Overall, no association of statistical significance was observed between disease stage and germline positive rate. The intermediate-/low-risk patients, who would not be indicated for germline testing based on current guidelines, had a positive rate of 14% (including P/LP variants and IRAs), the study authors wrote. Of the 36 intermediate-/low-risk patients with positive variants, 27(75%) had variants in clinically actionable genes.

Notably, 71% of patients who tested positive had P/LP variants that confers eligibility for gene-specific targeted agents or clinical trials based on variants in homologous repair or mismatch repair genes, the authors added.

These data imply that broader testing criteria could help to better inform care for many patients who might otherwise be overlooked for testing, according to the authors. By reducing barriers to testing, the authors conclude that more patients with prostate cancer would have access to crucial actionable genetic information that could lead to more targeted treatment approaches that could potentially improve outcomes.

New Recommendations Call for Increased Access to Germline Testing

The 2019 Philadelphia Prostate Cancer Consensus Conference, which brought together healthcare experts, stakeholders, and leaders from national organizations, was held to address challenges with germline testing in clinical practice and to map out a framework to increase accessibility to testing in the precision medicine era.

To do this, the panel set 3 goals: to define optimal germline testing approaches that comprise expanded panel testing options and evolving genetic data, to determine consistent germline testing indications and management, and to establish alternative genetic evaluation models in order to compensate for the shortage of genetic counseling services.3

A total of 97 participants attended the conference; these included experts in urology, medical oncology, radiation oncology, clinical genetics, and genetic counseling spaces, among others. In total, 76 participants were included on the final voting panel.

Panel members conducted a literature review with thematic topics that focused on prostate cancer risk, germline mutations by clinical and molecular characteristics of the disease, clinical multigene testing data, germline mutations in diverse populations, genetic testing capabilities and considerations, genetic counseling implementation, NCCN genetic testing guidelines, genetic testing for precision medicine in the metastatic setting, germline implications for active surveillance of early-stage disease, and germline implications for early disease detection.

Large germline panels and somatic testing were recommended for metastatic prostate cancer. Reflex testing to examine priority genes followed by expanded testing was recommended for several scenarios. Investigators determined these priority genes to be BRCA1/2 and mismatch repair genes with regard to metastatic disease treatment, and ATM in broader testing to help determine clinical trial eligibility. Additionally, BRCA2 was suggested for active surveillance discussions.

Upon completion of their review, the panel established criteria for germline prostate cancer genetic testing. Men with metastatic disease, including those with castration-resistant or castration-sensitive prostate cancer, meet the criteria for testing. In order for patients with nonmetastatic disease to be considered for genetic testing, they must either be of Ashkenazi Jewish ancestry, have advanced disease, have intraductal or ductal pathology, or be grade group 4 (Gleason sum 8) or above. Patients who have a brother or father, or 2 or more male relatives, who received a prostate cancer diagnosis and were under 60 years of age, who died from prostate cancer, or who had metastatic disease should also be considered for testing.

For those with metastatic disease, priority germline testing was recommended for those with BRCA1/2, DNA MMR genes, and further gene testing based on family history. Somatic next-generation sequencing was recommended for all men with metastatic disease. Additionally, confirmatory germline testing for somatic mutations was recommended for those with BRCA2 genes.

Reflex testing may be optimal for patients with nonmetastatic disease, according to the panel. with a recommendation to test for BRCA2 variants. For patients without a prostate cancer diagnosis but with an applicable family history, priority genes for risk assessment include BRCA2 and HOXB13.

References:

More:
Increased Access to Germline Testing Needed in Prostate Cancer - OncLive

Genetics

Cancer Genetics and StemoniX Sign Definitive Agreement to Merge – GlobeNewswire

Combined Company Positioned to Offer Best-in-Class and Innovative Drug Discovery Solutions

RUTHERFORD, NJ and MAPLE GROVE, MN, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the Company) (Nasdaq: CGIX), and StemoniX, Inc., today announced the entry into a definitive merger agreement. Cancer Genetics is a leader in drug discovery and preclinical oncology and immuno-oncology services. StemoniX, a privatecompany, isa leader in developing high-throughput disease-specifichuman organoid platforms integrated withleading-edge data science technologies. Under the terms of the merger agreement, StemoniX will merge with a newly formed subsidiary of Cancer Genetics in an all-equity transaction. Upon shareholder approval, the combined company expects to remain listed on the Nasdaq Stock Market. StemoniX will retain its name and become a wholly-owned subsidiary of Cancer Genetics.

The transaction will position the combined company to harness the synergies between two critical modalities of drug discovery and development - advanced animal models and relevant human high-throughput organoid platforms. The resulting integration of scientific and technology-based expertise, skilled management teams, and ability to offer customers an end-to-end platform will de-risk and accelerate development of preclinical and clinical pipelines for biopharma partners as well as for the proprietary pipeline of the combined company. In combination, Cancer Genetics and StemoniX currently enjoy partnerships and R&D relationships with dozens of global pharmaceutical and biotechnology companies.

"The process of discovering and developing a new drug candidate takes years and comes with a price tag of hundreds of millions - or even billions - of dollars. However, we are at unique time in the drug discovery industry as the convergence of technological innovations in both biology and software will transform conventional workflows in time and accuracy. To convert the time-consuming and labor-intensive process of developing a drug for market, we now look to supplement traditional discovery and drug approval mechanisms to include humanized cell-based assays with artificial intelligence (AI) along with our core vivoPharm business. Given that our strategy and approach are strongly aligned with those of StemoniX, we are pleased to have moved forward with this proposed transaction," stated Jay Roberts, Chief Executive Officer of Cancer Genetics.

The pharma industry and society are at a critical pivot point. Viral pandemics and diseases lacking treatments require a new way of innovation. The proposed merger expects to expand our ability to engage with a larger audience of potential partners and expand our internal capabilities as we deliver on our mission to rapidly discover the safest and most effective therapeutics on behalf of our partners and our shareholders. The mission will stay consistent - allow scientists to quickly and economically conduct high-throughput toxicity and drug development studies in ready-to-assay plates containing functional microOrgans, stated Ping Yeh, Chief Executive Officer of StemoniX.

ABOUT THE TRANSACTION

Pursuant to the merger agreement, Cancer Genetics will acquire all of the outstanding capital stock of StemoniX in exchange for a number of shares of its common stock which will represent approximately 78% of the outstanding common stock of Cancer Genetics, subject to certain adjustments and prior to the effects of the financing referred to below, with the current equity holders of Cancer Genetics retaining 22% of the common stock immediately following the consummation of the merger.

The Boards of Directors of both companies have approved the proposed merger, which is expected to close in the fourth quarter of 2020, subject to the approval of the shareholders of both Cancer Genetics and StemoniX, financing and other customary closing conditions.

H.C. Wainwright & Co. is acting as financial advisors to the Board of Directors of Cancer Genetics, and Lowenstein Sandler is acting as its legal counsel. Northland Securities, Inc. is acting as financial advisor to the Board of Directors of StemoniX and Taft, Stettinius & Hollister is acting as its legal counsel.

ABOUT CANCER GENETICS

Through its vivoPharm subsidiary, Cancer Genetics offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages, valued by the pharmaceutical industry, biotechnology companies and academic research centers. The Company is focused on precision and translational medicine to drive drug discovery and novel therapies. vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. vivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities. For more information, please visit http://www.cancergenetics.com.

ABOUT STEMONIX, INC.

StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPSC) cell-derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate, and consistent, these human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. Through collaborations with drug discovery organizations, StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes custom human iPSC disease models at large scale for high-throughput screening. With leading-edge iPSC technologies and data science, StemoniX is helping global institutions bring the most promising medicines to patients. To learn more about how StemoniX products and services are accelerating discoveries, please visit http://www.StemoniX.com.

For more information, please visit or follow CGI at:

http://www.cancergenetics.com

Twitter: @Cancer_Genetics

And StemoniX at:

http://www.StemoniX.com

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.s expectations regarding satisfaction of closing conditions, consummation of the merger, future financial and/or operating results, and potential for our services, future revenues or growth in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as will, believes, plans, anticipates, expects, estimates) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our ability to satisfy all closing conditions to the merger, our attempts to adapt to the global coronavirus pandemic, achieve profitability by increasing sales of our pre-clinical services, maintain our existing customer base and avoid cancellation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs and conditions to the merger, properly evaluate strategic options, and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2019 and Form 10-Q for the quarter ended June 30, 2020, along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Investor Contacts:Jennifer K. Zimmons. Ph.D.Investor RelationsZimmons International Communications, Inc.Email: jzimmons@zimmonsic.comPhone: +1.917.214.3514

Continue reading here:
Cancer Genetics and StemoniX Sign Definitive Agreement to Merge - GlobeNewswire

Genetics

Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline Following European Commission Approval of BLENREP…

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive a milestone payment from GlaxoSmithKline (GSK) triggered by European Commission conditional marketing authorisation for GSKs BLENREP (belantamab mafodotin), an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) that utilizes Seattle Genetics proprietary technology. BLENREP was developed and will be commercialized by GSK. In addition to the milestone payment, Seattle Genetics is entitled to royalties on BLENREP product sales. BLENREP was approved as monotherapy for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

This is the second collaborator program utilizing our ADC technology to receive European Commission approval in 2020, and rapidly follows the FDA approval of BLENREP earlier this month, highlighting the potential of these novel therapies in the treatment of cancer patients globally, said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. Our ADC collaborator progress, along with the growth of Seattle Genetics marketed ADCs, ADCETRIS and PADCEV, and recent positive results of tisotumab vedotin from our ADC pipeline, underscore our leadership in ADCs to treat cancer.

BLENREP was granted PRIME (PRIority MEdicines) designation in 2017 and the application was reviewed under the European Medicines Agencys (EMA) accelerated assessment procedure, which is given if the Committee for Medicinal Products for Human Use of the EMA determines the treatment is of major interest from a public health perspective and represents a therapeutic innovation.

Seattle Genetics ADC technology combines the specificity of monoclonal antibodies, innovative linker systems and potent cell-killing agents to treat cancer. The technology has been licensed to several companies. Under the terms of these agreements, each licensee company has rights to use the technology with antibodies against specified targets. The licensee is responsible for research, product development, manufacturing and commercialization. Seattle Genetics is entitled to receive fees, progress-dependent milestone payments and royalties on worldwide net sales of any resulting ADC products.

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) and PADCEV (enfortumab vedotin-ejfv) use the Companys industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. TUKYSA (tucatinib), a small molecule tyrosine kinase inhibitor, is approved in certain HER2-positive metastatic breast cancers. The Company is headquartered in the Seattle, Washington area, with locations in California, Switzerland and the European Union. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to anticipated milestone payments, fees, and royalties due to the company from GSK and other licensees, the therapeutic uses of BLENREP, the importance of ADCs in treating cancer and the companys leadership in the field of ADCs. Actual results or developments may differ materially from those projected or implied in these forward-looking statements due to factors such as unanticipated delays in or other obstacles to the development or commercialization of ADCs subject to these license agreements and the receipt by the Company of consideration from the subject ADC licenses. More information about the risks and uncertainties faced by the Company is contained under the caption Risk Factors included in the companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Visit link:
Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline Following European Commission Approval of BLENREP...